Leyden Labs

Leyden Labs was founded in 2020 by a team of world-renowned biotechnology veterans and fresh talent who are dedicated to freeing humanity from the burden of respiratory viruses. The company has raised $187.1 million in funding from investors such as F-Prime Capital and Bluebird Ventures. The company has also established offices and laboratories in Boston, MA, USA, and Granada, Spain. Leyden Labs reported revenue of $6.8 million for FY 2022.

Leyden Labs is currently developing two product candidates: PanFlu and PanCor. PanFlu is a nasal spray that contains an antibody called CR9114 that targets a common region of the influenza hemagglutinin protein. This antibody can neutralize all types of influenza viruses, including seasonal, pandemic, and avian strains. PanFlu is currently in Phase 1 clinical trials. PanCor is a nasal spray that contains an antibody called CR3022 that targets a common region of the coronavirus spike protein. This antibody can neutralize many types of coronaviruses, including SARS-CoV-2 and its variants. PanCor is expected to enter clinical trials in 2022.

Leyden Labs’ products have the potential to revolutionize the way we prevent and treat respiratory viral infections. They could offer a convenient, accessible, and universal solution that could empower people to live their lives to the fullest. Leyden Labs’ vision is to protect humanity from what comes next.

Foundation: 2020
Headquarters: Amsterdam, Noord-Holland, Netherlands

Website: https://leydenlabs.com